{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:56:58Z","timestamp":1787014618114,"version":"build-2736575974"},"reference-count":85,"publisher":"Wiley","issue":"7-8","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":4192,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[1997,11]]},"abstract":"<jats:p>\n                    <jats:bold>Summary.<\/jats:bold>\n                    Fluconazole dosages greater than 800 mg day\n                    <jats:sup>\u20101<\/jats:sup>\n                    have been reported in about 900 patients treated for candidemia, oropharyngeal candidiasis and cryptococcal meningitis in HIV\u2010infected patients, and for initial therapy of endemic mycoses*. In patients with life\u2010threatening infections caused by\n                    <jats:italic>Candida<\/jats:italic>\n                    spp.,\n                    <jats:italic>Cryptococcus neoformans<\/jats:italic>\n                    and\n                    <jats:italic>Coccidioides immitis<\/jats:italic>\n                    , results of a limited number of dose\u2010finding trials with non\u2010neutropenic and HIV\u2010infected patients show dose\u2010dependent responses. These study results indicate that higher daily doses of fluconazole than are currently approved for these indications are well tolerated and tend to provide better clinical efficacy in selected patient populations. An excellent safety profile of dosages up to 2000 mg day\n                    <jats:sup>\u20101<\/jats:sup>\n                    and linear predictable pharmacokinetics up to 1600 mg day\n                    <jats:sup>\u20101<\/jats:sup>\n                    appear to justify further clinical investigations to better determine the optimum dosage and duration of treatment.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Zusammenfassung.<\/jats:bold>\n                    Der klinische Einsatz von Fluconazol in Dosierungen  800 mg\/die ist bei etwa 900 Patienten f\u00fcr die Indikationen Candid\u00e4mie, oropharyngeale Candidose und\n                    <jats:italic>Cryptococcus<\/jats:italic>\n                    \u2010Meningitis bei HIV\u2010infizierten Patienten sowie bei der Akuttherapie endemischer Mykosen bereits gut dokumentiert**. Insbesondere bei Patienten mit lebensbedrohlichen, durch\n                    <jats:italic>Candida<\/jats:italic>\n                    spp.,\n                    <jats:italic>Cryptococcus neoformans<\/jats:italic>\n                    sowie durch\n                    <jats:italic>Coccidioides immitis<\/jats:italic>\n                    verursachten Infektionen zeigen die Ergebnisse einer begrenzten Anzahl von Dosisfindungsstudien mit immunkompetenten und HIV\u2010infizierten Patienten dosisabh\u00e4ngige Ansprechraten. Dies stellt ein wesentliches Argument f\u00fcr die Applikation auch hoher Fluconazoldosen dar, wobei die Evaluierung dieses Sachverhaltes noch nicht abgeschlossen ist. Die gute Vertr\u00e4glichkeit auch bei Dosierungen bis zu 2000 mg\/die sowie die vorhersagbare, lineare Pharmakokinetik bis zu 1600 mg\/die liefern konkrete Anhaltspunkte f\u00fcr die gro\u00dfe therapeutische Sicherheit von Fluconazol und rechtfertigen weitere prospektive, randomisierte klinische Pr\u00fcfungen mit m\u00f6glichst homogenen Patientenkollektiven zur Definition der optimalen Dosierung und Behandlungsdauer.\n                  <\/jats:p>","DOI":"10.1111\/j.1439-0507.1997.tb00231.x","type":"journal-article","created":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T12:48:20Z","timestamp":1240577300000},"page":"267-277","source":"Crossref","is-referenced-by-count":38,"title":["High\u2010dose therapy with fluconazole \u2265 800 mg day\n                    <sup>\u20101<\/sup>"],"prefix":"10.1111","volume":"40","author":[{"given":"K. H.","family":"Duswald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Penk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pittrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01962067"},{"key":"e_1_2_1_3_2","first-page":"15","article-title":"Predominant pathogens in hospital infections","volume":"28","author":"Jarvis W. R.","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.5.1247"},{"issue":"3","key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0002-9343(91)90349-3","article-title":"Secular trends in nosocomial primary bloodstream infections in the United States, 1980\u20131989","volume":"89","author":"Banerjee S. N.","year":"1991","journal-title":"Am J Med"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1988.00380120094019"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/archinte.1989.00390100145030","article-title":"Risk factors for hospital\u2010acquired candidemia: a matched case\u2010control study","volume":"149","author":"Wey S. B.","year":"1989","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/clind\/15.3.414"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.mi.42.100188.002505"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.6.1531"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-4453(93)92761-K"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(94)95926-9"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/172.2.599"},{"key":"e_1_2_1_14_2","volume-title":"National Committee for Clinical Laboratory Standards","author":"National Committee for Clinical Laboratory Standards","year":"1995"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.2.235"},{"key":"e_1_2_1_16_2","unstructured":"NCCLS Subcommittee on Antifungal Susceptibility Tests: Summary minutes on the Open meeting held June 1 1996 in Reston VA (unpublished)."},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.1996.tb00530.x"},{"key":"e_1_2_1_18_2","volume-title":"Fluconazole versus Amphotericin B for Candidemia in Non\u2010neutropenic Patients: A Multicenter Randomized Trial","author":"Phillips P.","year":"1995"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1001\/archinte.1995.00430220087009","article-title":"Therapeutic Approaches in Patients with Candidemia","volume":"155","author":"Nguyen M. H.","year":"1995","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.10.2495"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90300-X"},{"issue":"74","key":"e_1_2_1_22_2","first-page":"495","article-title":"Traitement par doses croissantes de la candidose oropharyng\u00e9e resistant au fluconazole","volume":"126","author":"Pagani J. L.","year":"1996","journal-title":"Schweiz Med Wochenschr"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/18.2.240"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-60377-8_77"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.1996.tb00508.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1996.03085.x"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.5.964"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01711909"},{"key":"e_1_2_1_29_2","volume-title":"Algorithm and Explanation: Approach to the Surgical Patient at Risk for Candidiasis","author":"Anaissie E.","year":"1994"},{"key":"e_1_2_1_30_2","first-page":"217","article-title":"Hematogenous Candidiasis: A review of therapeutic studies of fluconazole and amphotericin B and recommendations for management","volume":"5","author":"Abi\u2010Said D.","year":"1995","journal-title":"J Mycol Med"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0934-8840(11)80630-4"},{"key":"e_1_2_1_32_2","first-page":"1","article-title":"Interventionstherapie von Infektionen und Fieber unklarer Genese bei neutropenischen Patienten mit malignen h\u00e4matologischen Grunderkrankungen","volume":"10","author":"Meyer P.","year":"1992","journal-title":"Zeitschr Antimicrob Antineoplast Chemother"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/36.5.751"},{"key":"e_1_2_1_34_2","first-page":"93","article-title":"Azole resistance in yeasts","volume":"32","author":"Warnock D. W.","year":"1996","journal-title":"J Infect"},{"key":"e_1_2_1_35_2","first-page":"195","article-title":"Candida\u2010Infektionen in der Intensivmedizin","volume":"45","author":"Presterl E.","year":"1996","journal-title":"Anaesthesist"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.3.690"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/170.1.238"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.5.838"},{"key":"e_1_2_1_39_2","unstructured":"Milefchik E. Leal M. Haubrich R. H. Haghighat D. Bozzette S. A.&Larsen R. A.High Dose Fluconazole with and without Flucytosine for AIDS Associated Cryptococcal Meningitis. WS\u2010B12\u20105 9. International Conference on AIDS June 7\u201311 1993 Berlin Germany."},{"key":"e_1_2_1_40_2","unstructured":"Larsen R. A.Combination Therapy for Cryptococcosis and Speculations for Future Therapy. V3 ConferenceCryptococcus& Cryptococcosis September 2226 1996 Paris France."},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/19.5.975-a"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199312000-00028"},{"key":"e_1_2_1_43_2","volume-title":"Fluconazole with and without Flucytosine for AIDS\u2010Related Cryptococcal Meningitis in Uganda","author":"Tomberlin M. G.","year":"1994"},{"key":"e_1_2_1_44_2","unstructured":"Marriott D. J. E.Long\u2010term high dose fluconazole as salvage therapy for AIDS related cryptococcal meningitis: clinical and autopsy findings. Cryptococcosis Meeting 1993 Milano Italy."},{"key":"e_1_2_1_45_2","first-page":"873","article-title":"Treatment of Cryptococcal Meningitis in Non\u2010HIV Infected Patients\u2014A Randomized Comparative Trial","volume":"23","author":"Pappas P. G.","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"2","key":"e_1_2_1_46_2","first-page":"56","article-title":"Die Therapie der Candidose und Cryptococcose bei AIDS","volume":"37","author":"Just\u2010N\u00fcbling G.","year":"1994","journal-title":"Mycoses"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/19.4.741"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199102283240902"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199203193261203"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199605040-00003"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.5.996"},{"key":"e_1_2_1_52_2","first-page":"809","article-title":"Histoplasmosis in the Acquired Immunodeficiency Syndrome (AIDS): Treatment with Itraconazole and Fluconazole","volume":"6","author":"Sharkey\u2010Mathis P. K.","year":"1993","journal-title":"J Acquired Immune Deficiency Syndrome"},{"key":"e_1_2_1_53_2","volume-title":"Fluconazole Treatment for Histoplasmosis in AIDS: Prospective Multicenter Non\u2010comparative Trial","author":"Wheat L.","year":"1994"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-5-199509010-00006"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.1.46"},{"key":"e_1_2_1_56_2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1128\/CMR.8.1.146","article-title":"Endemic Mycoses in AIDS: A Clinical Review","volume":"8","author":"Wheat J.","year":"1995","journal-title":"Clin Microb Rev"},{"key":"e_1_2_1_57_2","volume-title":"Mykosen in der operativen Medizin","author":"Penk A.","year":"1997"},{"key":"e_1_2_1_58_2","volume-title":"Efficacy, Safety and Pharmacokinetics of High Dose Fluconazole in Patients with Fungal Infections","author":"Anaissie E. J.","year":"1992"},{"key":"e_1_2_1_59_2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1439-0507.1995.tb00407.x","article-title":"Fluconazole in the treatment of pulmonary zygomycosis","volume":"38","author":"Koszyca B.","journal-title":"Mycoses"},{"issue":"1","key":"e_1_2_1_60_2","first-page":"568","article-title":"A Pan\u2010American 5\u2010Year Study of Fluconazole Therapy for Deep Mycoses in the Immunocompetent Host","volume":"14","author":"Diaz M.","year":"1992","journal-title":"Clin Infect Dis"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)64828-3"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.1997.tb00167.x"},{"key":"e_1_2_1_63_2","volume-title":"Mykosen in der operativen Medizin","author":"Pittrow L.","year":"1997"},{"key":"e_1_2_1_64_2","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/jac\/25.4.720","article-title":"High dose oral fluconazole for oropharyngeal candidosis in AIDS","volume":"25","author":"Ansari A. M.","year":"1990","journal-title":"JAC"},{"key":"e_1_2_1_65_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/jac\/37.suppl_B.71","article-title":"Treatment of fungal infection in AIDS","volume":"37","author":"Hood S.","year":"1996","journal-title":"JAC"},{"key":"e_1_2_1_66_2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1128\/CMR.8.4.515","article-title":"Cryptococcosis in the Era of AIDS\u2014100. Years after the Discovery of Cryptococcus neoformans","volume":"8","author":"Mitchell T. G.","year":"1995","journal-title":"Clin Microbiol Rev"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1093\/clind\/16.3.349"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-1-199307010-00005"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01967060"},{"key":"e_1_2_1_70_2","first-page":"299","article-title":"Systemische Pilzinfektionen bei h\u00e4matologischen Neoplasien","volume":"89","author":"Pfaffenbach B.","year":"1994","journal-title":"Med Klinik"},{"key":"e_1_2_1_71_2","unstructured":"Duswald K. H. Zettl R. Lederle J. Penk A. Pittrow L.High\u2010Dose Fluconazole 800mg\/day in ICU\u2010Patients with Candidiasis. 20th International Congress of Chemotherapy 1997 Sydney. Abstract 5055."},{"key":"e_1_2_1_72_2","unstructured":"Milefchik E. Leal M. Haubrich R. Bozzette S. Tilles J. Leedom J. McCutchan J. A. Larsen R. A.A Phase II Dose Escalation Trial of High Dose Fluconazole With and Without Flucytosine for AIDS Associated Cryptococcal Meningitis. 4th Conference on Retroviruses and Opportunistic Infections.January 2227 1997. Washington. Abstract 640."},{"key":"e_1_2_1_73_2","first-page":"83","article-title":"High dose fluconazole can be safely administered in AIDS patients with severe oropharyngeal candidiasis: a case report","volume":"76","author":"Bernstein L.","year":"1996","journal-title":"Ann Allergy"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)65949-1"},{"key":"e_1_2_1_75_2","unstructured":"Pappas P. G. Kauffman C. A. McKinsey D. S. Bradsher R. W. Sharkey P. K. Chapman S. J. J. J. Greenfield R. Newman C. Dismukes W. E.Fluconazole for the Treatment of Blastomycosis. Histoplasmosis and Sporotrichosis. 32nd Annual IDSA Meeting October 79 1994 Orlando Abstract 83."},{"key":"e_1_2_1_76_2","unstructured":"Link H. Maschmeyer G. Meyer P. Hiddemann W. Schrappe M. Helmerking M.&Adam D.Antimicrobial Therapy in Febrile Neutropenic Patients; Results of the Prospective Studies of the Paul\u2010Ehrlich\u2010Society of Chemotherapy. 6th BICONMay 24 1996. Leipzig Abstract 21."},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.2.365"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199612000-00011"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01974619"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01974617"},{"key":"e_1_2_1_81_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF01974618","article-title":"Efficacy and Safety of Fluconazole in the Treatment of Systemic Fungal Infections in Pediatric Patients","volume":"13","author":"Presterl E.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"e_1_2_1_82_2","unstructured":"Koletar S. L. O'Grady N. P.Treatment of Disseminated Histoplasmosis. IXth International Conference on AIDS June 611 1993 Berlin Abstract 1391."},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.1994.tb00426.x"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/14.Supplement_1.S54"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)61381-0"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.Supplement_2.S148"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0507.1997.tb00231.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1439-0507.1997.tb00231.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T02:44:51Z","timestamp":1693449891000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0507.1997.tb00231.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,11]]},"references-count":85,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[1997,11]]}},"alternative-id":["10.1111\/j.1439-0507.1997.tb00231.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1439-0507.1997.tb00231.x","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,11]]}}}